Alder BioPharmaceuticals (ALDR) & Its Competitors Critical Review
Alder BioPharmaceuticals (NASDAQ: ALDR) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Alder BioPharmaceuticals to related businesses based on the strength of its dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.
Volatility & Risk
Alder BioPharmaceuticals has a beta of 2.48, meaning that its stock price is 148% more volatile than the S&P 500. Comparatively, Alder BioPharmaceuticals’ rivals have a beta of 5.95, meaning that their average stock price is 495% more volatile than the S&P 500.
Earnings and Valuation
This table compares Alder BioPharmaceuticals and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Alder BioPharmaceuticals||$110,000.00||-$156.25 million||-2.00|
|Alder BioPharmaceuticals Competitors||$284.49 million||$33.78 million||81.50|
Alder BioPharmaceuticals’ rivals have higher revenue and earnings than Alder BioPharmaceuticals. Alder BioPharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Alder BioPharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Alder BioPharmaceuticals Competitors||-5,310.77%||-218.27%||-39.48%|
Institutional and Insider Ownership
96.9% of Alder BioPharmaceuticals shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 10.6% of Alder BioPharmaceuticals shares are owned by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a summary of current ratings and target prices for Alder BioPharmaceuticals and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Alder BioPharmaceuticals Competitors||866||3222||11685||232||2.70|
Alder BioPharmaceuticals presently has a consensus price target of $30.58, indicating a potential upside of 185.83%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.04%. Given Alder BioPharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Alder BioPharmaceuticals is more favorable than its rivals.
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder’s third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.
Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.